Davunetide

Overview

Davunetide (NAP, NAPVSIPQ) is an 8-amino acid neuroprotective peptide derived from the activity-dependent neuroprotective protein (ADNP). It was first identified as a neuroprotective factor secreted by VIP-stimulated astrocytes and represents the shortest active fragment capable of protecting neurons. It has been characterized as the first drug to improve memory performance by targeting microtubule stability mechanisms underlying neurofibrillary tangles. Davunetide was studied in Phase II clinical trials for schizophrenia, Alzheimer's disease, and progressive supranuclear palsy (PSP).

Mechanism of Action

Davunetide protects neurons through microtubule stabilization — specifically preventing neurofibrillary tangle formation and repairing existing microtubule network damage. It reduces hyperphosphorylation of tau protein through modulation of PI3K/Akt, MAPK/ERK, and Src kinase signaling cascades. By stabilizing the cytoskeletal network, it preserves synaptic integrity and axonal transport, both critical for cognitive function. It also promotes neuritic outgrowth (70% increased axon length vs controls) and protects neurons against a broad range of toxins relevant to Alzheimer's and PSP.

Potential Benefits

• Microtubule stabilization preventing neurofibrillary tangle formation
• Reduction of tau hyperphosphorylation in multiple models
• Neuroprotection against diverse neurotoxins
• 70% increase in axon length versus controls in neuritic outgrowth studies
• Phase II improvements in verbal recall and visual working memory (digit span, delayed-match-to-sample)
• Significant functional capacity improvements in schizophrenia trial (UPSA scale)
• Intranasal delivery enabling non-invasive CNS delivery

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

Clinical doses: 5-30 mg intranasal twice daily. Phase I: dose-related pharmacokinetics confirmed after intranasal administration. Half-life short; intranasal delivery bypasses first-pass.

Amino Acid Sequence

Side Effects & Safety

• Well-tolerated in Phase I/II studies
• No significant adverse events reported at clinical doses
• Mild nasal irritation with intranasal form

Synergistic Compounds

The following compounds have been studied alongside Davunetide for potential complementary or synergistic effects:

Related Peptides

Learn More

References & Further Reading

• [object Object]
• [object Object]
• [object Object]